Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on August 31st, 2016 by Dr Andrew A. ParsonsPharma R&D
According to Jon Kolko (HBR 2015), the age of “design thinking” is here. Several high tech companies appear to be taking simple design principals in moving from selling products to providing services for their users or clients. (more…)
Posted on August 29th, 2016 by Betsy DavisPharma R&D
In a new feature in The Atlantic, author Jessa Gamble makes the case that Modern Medicine Is Too Reliant on Short-Term Studies, too often preferring the instant gratification that comes from a short study, only to find those results soon challenged by yet another short-term study.
Posted on August 26th, 2016 by Dr. Makarand Jawadekar, Ph.DChemistry
In January of 2015, President Barack Obama launched the Precision Medicine Initiative, which brought to the forefront the growing understanding and need for individually tailored and customized treatments for patients.
Posted on August 24th, 2016 by Patrick C. May, PH.D.Pharma R&D
In a previous blog, I provided a few thoughts on tau-related drug discovery news coming out of the recent Alzheimer’s Association International Conference (AAIC16) in Toronto, Canada. In this post, I will highlight some of the research from the conference on gamma and beta-secretase, (more…)
Posted on August 22nd, 2016 by Amram EwooPharma R&D
One of the strongest arguments for using the molecular biology modeling tool Pathway Studio is the rich content underlying its knowledge database. This was driven home recently in a conversation with the DNA/RNA sequencing company Illumina. (more…)
Posted on August 19th, 2016 by J.-P. Clement MDPharmacovigilance
Measuring the compliance of a defined set of variables is key for functions like pharmacovigilance, where there is intense reporting to different regulatory and non-regulatory entities with strict regulations and high inspection risk. (more…)
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.